Current Research Studies

We are currently enrolling patients to evaluate the efficacy and safety of an oral medication in participants, who have either refractory or unexplained chronic cough.

Potential subjects must meet the following criteria:

• ≥ 18 years old
• Chronic cough for ≥ 1 year and a diagnosis of refractory cough or unexplained chronic cough
• X-ray or CT scan of the thorax (within 5 years of screening/visit 1 and after onset of chronic cough)
• Have a score of ≥ 40mm on cough severity VAS at both Screening and Baseline visits
• Nonsmoker
• FEV₁/FVC ratio >60% within last 12 months while clinically stable (not during upper respiratory infection)
• Not using ACE inhibitors within 3 months of Screening/Visit 1
• NO history of adverse drug reaction or anaphylaxis to sulfonamides

Other conditions may apply. Please contact research@allergicdisease.com for more information

We are currently enrolling patients to evaluate the efficacy and safety of a biologic in adults and adolescents with severe uncontrolled asthma.

Potential subjects must meet the following criteria:

• Between the ages of 12 and 80
• Documented physician diagnosed severe asthma for at least 12 months prior to visit 1.
• History of two or more asthma exacerbations that required treatment with prednisone (IM or PO) in the past 12 months.
• Documented treatment with a high dose ICS/LABA for at least three months

Other conditions may apply. Please contact research@allergicdisease.com for more information

The objective of this study is to describe patient characteristics, treatment patterns, and outcomes among adults with severe asthma who are not controlled with ICS or monoclonal therapy.

Potential subjects must meet the following criteria:

1. ≥ 18 years old
2. Severe asthma for at least 12 months prior to enrollment
3. Currently receiving care from our practice
4. Meeting at least ONE of the following three criteria (1, 2, or 3)
   1. Uncontrolled asthma on highest dose of ICS or ICS/LABA
   2. Current use of FDA approved biologic for treatment of severe asthma (Xolair, Cinqair, Nucala, Fasenra)
   3. Use of prednisone or other immunosuppressant for approximately 50% or more of last 12 months for treatment of severe asthma

Uncontrolled Asthma is defined as one of the following:
1. Poor symptom control ACQ >1.5, ACT <20
2. Frequent sever exacerbations: 2 or more burst of prednisone in last 12 months.
3. Severe exacerbation: at lease one hospitalization, ICU or ventilator in last 12 months.
4. FEV₁ <80%